Safety and efficacy of biosimilar filgrastim in patients with lung cancer undergoing neutropenia-inducing chemotherapy: A sub-analysis of the NEXT study

被引：0

作者：

Kamioner, D. ^{[1
]}

Lepretre, S. ^{[2
]}

Maloisel, F. ^{[3
]}

Berthou, C. ^{[4
]}

Albrand, H. ^{[5
]}

机构：

[1] Hop Prive Ouest Parisien, Oncol, Trappes, France

[2] Henri Becquerel Hosp, Hematol, Rouen, France

[3] St Anne Clin, Hematol & Oncol, Strasbourg, France

[4] Hop Morvan, Hematol, Brest, France

[5] Hospira France, Hospira, Meudon, France

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30592-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1501

引用

页码：S204 / S205

页数：3

共 50 条

[1] Safety and efficacy of biosimilar filgrastim in patients with colorectal cancer undergoing neutropenia-inducing chemotherapy: A sub-analysis of the NEXT study
Kamioner, D.
Lepretre, S.
Maloisel, F.
Berthou, C.
Albrand, H.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S242 - S242
[2] Safety of biosimilar filgrastim in patients with lymphoma undergoing neutropenia-inducing chemotherapy: a sub-analysis of the NEXT study
Lepretre, S.
Maloisel, F.
Kamioner, D.
Berthou, C.
Albrand, H.
BONE MARROW TRANSPLANTATION, 2015, 50 : 5623 - 5624
[3] Safety of Biosimilar Filgrastim in Patients Undergoing Neutropenia-Inducing Chemotherapy: The Next Study
Lepretre, Stephane
Maloisel, Frederic
Kamioner, Didier
Berthou, Christian
Albrand, Helene
BLOOD, 2014, 124 (21)
[4] Safety and efficacy of prophylactic and curative biosimilar filgrastim in patients undergoing neutropenia-inducing chemotherapy: The NEXT study
Maloisel, F.
Lepretre, S.
Kamioner, D.
Berthou, C.
Albrand, H.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S243 - S243
[5] Safety of biosimilar filgrastim in elderly patients undergoing neutropenia-inducing chemotherapy: a subanalysis of the NEXT study
Kamioner, Didier
Maloisel, Frederic
Lepretre, Stephane
Berthou, Christian
Albrand, Helene
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[6] Safety of biosimilar filgrastim in patients with breast cancer undergoing neutropenia-inducing chemotherapy: A subanalysis of the NEXT study.
Lepretre, Stephane
Maloisel, Frederic
Kamioner, Didier
Berthou, Christian
Albrand, Helene
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[7] SAFETY OF BIOSIMILAR FILGRASTIM IN PATIENTS WITH LYMPHOMA AND MYELOMA UNDERGOING NEUTROPENIA-INDUCING CHEMOTHERAPY: A SUBANALYSIS OF THE NEXT STUDY
Lepretre, S.
Maloisel, F.
Kamioner, D.
Berthou, C.
Albrand, H.
HAEMATOLOGICA, 2015, 100 : 469 - 469
[8] Safety of Biosimilar Filgrastim in Patients with Haematological Malignancies Undergoing Neutropenia-Inducing Chemotherapy: A Subanalysis of the Next Study
Lepretre, Stephane
Maloisel, Frederic
Kamioner, Didier
Berthou, Christian
Albrand, Helene
BLOOD, 2014, 124 (21)
[9] Biosimilar filgrastim in the treatment of patients with breast cancer undergoing neutropenia-inducing chemotherapy: A subanalysis of the NEXT study
Albrand, H.
Kamioner, D.
Lepretre, S.
CANCER RESEARCH, 2016, 76
[10] BIOSIMILAR FILGRASTIM IN PATIENTS UNDERGOING NEUTROPENIA-INDUCING CHEMOTHERAPY: OVERALL RESULTS FROM THE NEXT OBSERVATIONAL STUDY
Maloisel, F.
Lepretre, S.
Kamioner, D.
Christian, B.
Albrand, H.
HAEMATOLOGICA, 2015, 100 : 470 - 470

← 1 2 3 4 5 →